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ABSTRACT
Background: Low-dose azithromycin is an effective therapy for persistent asthma; however, its benefit in
severe asthma is not defined.
Methods: Participants with severe asthma were identified from the AMAZES randomised, placebo-
controlled trial of long-term (48 weeks) low-dose azithromycin. Participants who met one of the following
severe asthma definitions were included: 1) Global Initiative for Asthma step 4 treatment with poor
asthma control (asthma control questionnaire score ⩾0.75); 2) International Severe Asthma Registry
definition; 3) American Thoracic Society and European Respiratory Society severe asthma definitions. The
rate of total exacerbations was calculated for each subgroup and efficacy of azithromycin compared with
placebo. Asthma-related quality of life was assessed before and after treatment along with adverse effects.
Results: Azithromycin significantly reduced asthma exacerbations in each group. In patients meeting the
American Thoracic Society and European Respiratory Society task force definition of severe asthma
(n=211), the rate of exacerbations with treatment was 1.2 per person-year, which was significantly less
than for placebo (2.01 per person-year), giving an incidence rate ratio (95% CI) of 0.63 (0.41, 0.96). The
proportion of participants experiencing at least one asthma exacerbation was reduced by azithromycin
from 64% to 49% (p=0.021). A similar beneficial treatment effect was seen in participants poorly
controlled with Global Initiative for Asthma step 4 treatment and those with International Severe Asthma
Registry-defined severe asthma. Azithromycin also significantly improved the quality of life in severe
asthma (p<0.05). Treatment was well tolerated, with gastrointestinal symptoms being the main adverse
effect.
Conclusion: Long-term, low-dose azithromycin reduced asthma exacerbations and improved the quality of
life in patients with severe asthma, regardless of how this was defined. These data support the addition of
azithromycin as a treatment option for patients with severe asthma.
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Low-dose azithromycin is effective therapy for persistent asthma. AMAZES supports AZM as a
treatment option for patients with severe asthma. Long-term, low-dose AZM reduces asthma
exacerbations and improves quality of life in patients with severe asthma. http://bit.ly/2LWyjYz
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Severe asthma is a high-cost, high-burden disease that affects between 3% and 10% of people with asthma
[1–3]. It is characterised by persistent poor symptom control and/or disease exacerbations that occur
despite maximal therapy with inhaled corticosteroids (ICSs) and long-acting bronchodilators. Although
severe asthma is uncommon, because of the high disease burden it accounts for up to 50% of healthcare
costs from asthma, and per-patient costs can be greater than other chronic diseases, including chronic
obstructive pulmonary disease (COPD) [4]. New therapies have been introduced to address this disease
burden in severe asthma and include monoclonal antibodies that target a subgroup with eosinophilic
disease. However, there is an ongoing need for additional therapies for severe asthma, especially for
noneosinophilic subtypes and for the residual exacerbation burden in eosinophilic disease.
Low-dose azithromycin (AZM) is an effective therapy for persistent asthma [5, 6]. It led to a 40%
reduction in severe asthma exacerbations, and a similar reduction in respiratory tract infections, when
adults with symptomatic persistent asthma, despite maintenance inhaled asthma therapy, received AZM
500 mg orally, three times per week, for 48 weeks [6]. AZM is effective in both eosinophilic and
noneosinophilic forms of asthma. The mechanism of this effect is not yet established and may involve
antibiotic and/or immunomodulatory mechanisms [7]. The treatment is well tolerated, but because of the
potential for individual and community antibiotic resistance, concern remains regarding where to place
AZM in current practice. Specific questions relate to the efficacy of AZM in severe asthma and the benefit
in noneosinophilic phenotypes of the disease.
Current asthma therapy follows a stepwise approach. Treatment options for patients who are symptomatic
on ICSs and long-acting β agonists (LABAs) include higher dose ICSs, maintenance low-dose oral
corticosteroids (OCSs), long-acting muscarinic agents (LAMAs), eosinophil targeted monoclonal antibody
therapy and bronchial thermoplasty. Low-dose AZM could potentially be added to this list. The AMAZES
trial which demonstrated efficacy of AZM in persistent asthma, also included patients with severe asthma,
which means there is an opportunity to examine the efficacy of AZM in severe asthma in order to inform
where AZM could be placed in the treatment options that are available for patients with severe asthma.
In this secondary analysis of the AMAZES trial, we sought to describe the effect of AZM in different
severe asthma subgroups in order to further inform treatment decisions. The subgroups were: 1) patients
with symptomatic asthma on Global Initiative for Asthma (GINA) step 4 therapy; 2) patients meeting the
International Severe Asthma Registry (ISAR) [8] definition of severe asthma; and 3) patients meeting the
American Thoracic Society (ATS)/European Respiratory Society (ERS) severe asthma task force definition
[2]. We hypothesised that AZM would be beneficial in each of these subgroups.
Methods
Clinical method
We investigated the effect of low-dose AZM in severe asthma by conducting a subgroup analysis of a
randomised control trial (RCT) of low-dose AZM in asthma. The AMAZES study [6] was a double-blind
placebo-controlled trial where 420 adults with persistent symptomatic asthma, despite the current use of
ICSs and long-acting bronchodilators, and who had no hearing impairment or prolongation of the
corrected QT interval, were randomised to receive 500 mg of AZM three times per week or identical
placebo for 48 weeks. Asthma exacerbations were recorded as the primary study outcome [6]. Severe
exacerbations were defined as a worsening of asthma symptoms that led to one of the following:
1) ⩾3 days of systemic corticosteroid treatment ⩾10 mg·day−1 of prednisone or equivalent or a temporary
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increase in a stable OCS maintenance dosage of ⩾10 mg·day−1 for ⩾3 days; 2) an asthma-specific
hospitalisation; or 3) an emergency department visit requiring systemic corticosteroids. Moderate
exacerbations were defined as any temporary increase in ICSs and/or antibiotics in conjunction with a
deterioration in asthma symptoms (change in asthma control questionnaire (ACQ), Δ ACQ6 ⩾ 0.5 or
increased diary symptom score) or any increase in β2-agonist use for ⩾2 days, or an emergency
department visit not requiring systemic corticosteroids.
Asthma quality of life was assessed at randomisation and at the end of treatment using a validated
questionnaire, the Asthma Quality of Life Questionnaire (AQLQ) [9]. Adverse events were assessed at each
study visit. The inflammatory phenotype was assessed using induced sputum, or if not available, blood
eosinophils. Noneosinophilic asthma was defined using baseline sputum eosinophils <3% or a blood
eosinophil count <300 cells·mL−1. The trial was approved by the institutional ethics committees and
registered at the Australian and New Zealand Clinical Trials Registry, number 12609000197235. All
patients provided written informed consent.
Definition of severe asthma
Severe asthma was defined as: 1) GINA step 4 treatment with poor asthma control (ACQ score ⩾0.75);
2) ISAR definitions of asthma on GINA step 4 or on GINA step 5 treatment [8]; or 3) ATS/ERS severe
asthma task force criteria (high-dose ICS plus a second controller and/or systemic corticosteroids) [2].
Analysis
Statistical analyses were performed using STATA 13 (StataCorp, College Station, TX, USA). Total asthma
exacerbations for each subgroup were analysed using a negative binomial regression with the length of
intervention treatment included as an offset and adjustment for clustering for study site. An interaction
term for subgroup and treatment was included in each model. The estimated treatment effect (i.e. the
incidence rate ratio (IRR) of AZM versus placebo), corresponding 95% confidence intervals (CIs) and a
two-sided p-value for the IRR were calculated. Exacerbation rates were calculated as the total number of
exacerbations per person divided by the number of days of follow-up, multiplied by 365 and expressed as
exacerbations per person-year. The proportion of participants experiencing ⩾1 exacerbation was compared
using a Chi-squared test. End of treatment AQLQ scores were compared between groups using ANOVA
adjusted for baseline measurement, phenotype and phenotype–treatment interactions. A p-value <0·05 was
considered statistically significant.
Results
Overall, 420 patients were randomly assigned from a total of 582 patients screened for participation, from
June 12, 2009 to January 31, 2015. A total of 213 patients (51%) were allocated to AZM treatment and 207
(49%) to placebo. The trial was completed by 334 (80%) patients, with similar numbers of trial
withdrawals in each group (figure 1) [6]. There were 211 patients with severe asthma (ATS/ERS), 344 with
GINA step-4 treatment who were poorly controlled, and 357 with ISAR-defined severe asthma (figure 2).
Participant characteristics for the ATS/ERS severe asthma subgroup are shown in table 1.
Severe asthma
The severe asthma group was a predominantly female population, with a mean age of 61 years and a high
prevalence of atopy (78%). They reported a long duration of asthma (33 years), poor symptom control
(ACQ 1.67), and moderate airflow obstruction (forced expiratory volume in 1 s (FEV1) 70% predicted)
despite therapy with high-dose ICSs and long-acting bronchodilators.
AZM significantly reduced asthma exacerbations in severe asthma by all definitions. The rate of asthma
exacerbations with placebo (2.01) was significantly reduced to 1.2 exacerbations per person-year with AZM
treatment (figure 2). The corresponding IRR (95% CI) was 0.63 (0.41, 0.96). The proportion of
participants experiencing at least one asthma exacerbation during treatment was reduced by AZM from
64% to 49% (p=0.021). A similar beneficial treatment effect was seen in participants poorly controlled or
uncontrolled with GINA step 4 treatment, and in those with severe asthma defined under ISAR criteria
(table 2 and figure 2). AZM treatment also significantly improved asthma-related quality of life in severe
asthma (table 3) (p=0.029).
In noneosinophilic asthma, AZM reduced the exacerbation rate in severe asthma defined as GINA step-4
treatment and using ISAR criteria (figure 3). The effect in ATS/ERS defined severe asthma showed a
similar trend but was not statistically significant due to insufficient power from the reduced sample size. In
severe eosinophilic asthma, AZM significantly reduced the rate of severe exacerbations, when defined using
each of the definitions: IRR 0.46, 0.45 and 0.49, for GINA 4, ISAR and ATS/ERS task force-defined severe
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162 excluded
  108 inclusion criteria not met
  26 withdrew consent
  2 adverse event
  14 lost to follow-up
  12 other reason
207 allocated to placebo
  96 severe asthma subgroup
  170 GINA 4 treatment
  175 ISAR definition
213 allocated to azithromycin
  115 severe asthma subgroup
  174 GINA 4 treatment
  182 ISAR definition
166 completed treatment
207 analysed intention to treat
168 completed treatment
213 analysed intention to treat
96 severe asthma subgroup
170 GINA 4 treatment
175 ISAR definition
115 severe asthma subgroup
174 GINA 4 treatment
182 ISAR definition
41 withdrawn
  12 lost to follow-up
  10 adverse events
  1 protocol violation
  6 withdrew consent
  12 other
45 withdrawn
  10 lost to follow-up
  15 adverse events
  1 protocol violation
  5 withdrew consent
  14 other
420 randomised
  211 severe asthma
  344 GINA 4 treatment
  357 ISAR definition
582 patients screened
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FIGURE 2 Effect of add-on azithromycin treatment on asthma exacerbations according to subgroup analyses.
Severe asthma (ATS/ERS): ⩾1000 µg of fluticasone equivalent inhaled corticosteroid and long-acting β agonist
combination. No significant interaction was present between subgroup and treatment. AZM: azithromycin;
IRR: incidence rate ratio; GINA: Global Initiative for Asthma; ATS: American Thoracic Society; ERS: European
Respiratory Society; ISAR: International Severe Asthma Registry.
https://doi.org/10.1183/23120541.00056-2019 4
ASTHMA | P.G. GIBSON ET AL.
TABLE 2 Proportion of subjects with severe asthma experiencing an exacerbation
Placebo Azithromycin p-value
Asthma GINA step 4 109/170 (64.1%) 80/174 (46.0%) 0.001
ISAR# 112/175 (64.0%) 84/182 (46.2%) 0.001
Severe asthma (ATS/ERS)¶ 62/96 (64.6%) 56/115 (48.7%) 0.021
GINA: Global Initiative for Asthma; ISAR: International Severe Asthma Registy. #: asthma GINA step 4 and
5; ¶: American Thoracic Society/European Respiratory Society.
TABLE 1 Participant characteristics for severe asthma using the American Thoracic Society/
European Respiratory Society task force definition
Variable Severe asthma (N=211)




Smoking history pack-years 9.0 (2.3–26.0)
Asthma history
Asthma duration years 33.8 (14.8–49.8)
ACQ score 1.7 (1.2–2.3)
Oral corticosteroid courses 1 (1–3), range 0–15
Medications
ICS daily dose BDP equivalent µg·day−1 2000 (2000–2000)
ICS/LABA 211 (100%)
Leukotriene modifier 10 (4.8%)
Long-acting muscarinic antagonist 54 (25.7%)
Theophylline 8 (3.8%)
ICS 17 (8.1%)
Oral corticosteroid 9 (4.3%)
Pre-B2 spirometry mean±SD
Pre-B2 FEV1 % predicted 70.4±18.9
Pre-B2 FVC % predicted 81±15.5
Pre-B2 FEV1/FVC % 66.8±11.8
Sputum phenotype (N=168)
Eosinophilic 73 (43.5%)
Data are presented as median (interquartile range) unless otherwise stated. ACQ: Asthma Control
Questionnaire; ICS: inhaled corticosteroid; BDP: beclomethasone dipropionate; LABA: long-acting
β2-agonist; pre-B2: pre-β2-agonist.
TABLE 3 Efficacy of azithromycin on quality of life in severe asthma at end of treatment
(observed data only)
Placebo Azithromycin p-value#
AQLQ mean score 5.45 (5.19–5.70)¶ 5.61 (5.41–5.82)+ 0.029
AQLQ Activity domain 5.55 (5.29–5.81)¶ 5.70 (5.49–5.90)+ 0.063
AQLQ Symptoms domain 5.28 (5.02–5.55)§ 5.49 (5.28–5.71)ƒ 0.031
AQLQ Emotions domain 5.37 (5.03–5.71)§ 5.57 (5.29–5.85)ƒ 0.017
AQLQ Environment domain 5.76 (5.49–6.02)§ 5.68 (5.46–5.91)ƒ 0.262
Data are presented as mean (95% CI) unless otherwise stated. No significant interaction was present.
AQLQ: Asthma Quality of Life Questionnaire. #: ANCOVA adjusted for baseline measurement, phenotype
(noneosinophilic/eosinophilic asthma) and phenotype–treatment interaction; ¶: n=95; +: n=113; §: n=96;
ƒ: n=115.
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asthma, respectively, all p<0.05. The effect size for total exacerbations was clinically significant (IRR 0.60)
but failed to reach statistical significance (figure 4).
Adverse effects
The rate of adverse events was similar in both treatment groups (table 4). In the AZM group there were 7
(6.1%) participants who withdrew from the study due to an adverse event, whereas in the placebo group
there were 7 (7.3%) participants who withdrew due to an adverse event. Diarrhoea was more common
with AZM, occurring in 41 (35.7%) of AZM-treated participants, compared with 22 (22.9%) of
placebo-treated patients. Diarrhoea was managed by temporary dose adjustment and did not result in
treatment withdrawal.
Discussion
We report that long-term low-dose AZM is effective in patients with severe asthma. These patients
experienced a significant reduction in asthma exacerbations with AZM therapy and improved health
status. The effect was consistent across different definitions of severe asthma, and also in severe
noneosinophilic and eosinophilic asthma. These data support the addition of AZM as a treatment option
for patients with severe asthma.
This study represents the largest RCT to assess the effect of AZM in severe asthma. The positive effect in
noneosinophilic asthma is consistent with prior reports, such as the AZISAST study that reported a
positive effect of AZM for 6 months in noneosinophilic severe asthma [5] and a smaller trial that showed
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FIGURE 3 Total exacerbations in noneosinophilic severe asthma American Thoracic Society (ATS) criteria:
high-dose inhaled corticosteroid and long-acting β2-agonist (LABA) (⩾1000 µg fluticasone and LABA
combination). AZM: azithromycin; IRR: incidence rate ratio; GINA: Global Initiative for Asthma; ISAR:






















0.0 0.2 0.60.4 0.8 1.0 1.61.41.2
FIGURE 4 Total exacerbations in severe eosinophilic asthma. AZM: azithromycin; IRR: incidence rate ratio;
GINA: Global Initiative for Asthma; ISAR: International Severe Asthma Registry; ATS: American Thoracic
Society; ERS: European Respiratory Society.
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[10]. A retrospective observational trial also reported a positive effect of AZM in severe asthma [11].
Collectively, these data provide evidence that AZM is effective in severe asthma, when defined using
several widely accepted definitions, and also in severe noneosinophilic asthma. The benefits are a
reduction in asthma exacerbations and an improvement in quality of life.
The existing treatment options for patients with severe asthma include LAMAs, biologics, maintenance
OCSs and bronchial thermoplasty. Each of these options has pros and cons. AZM could precede
maintenance OCS as it is less toxic. The main benefit of biologics in severe asthma is a reduction in severe
asthma exacerbations, and both AZM and anti-eosinophilic biologics reduce severe asthma exacerbations
by a similar degree. AZM may be more cost-effective than biologics and in addition, is effective in
noneosinophilic asthma, whereas current biologics are restricted to eosinophilic or allergic disease.
However, AZM may take longer to produce an effect, and an effect on hospital admissions is not yet
demonstrated with AZM. If there is a history of infective bronchitis, AZM is effective where other options
are not. Overall, these considerations support the early use of AZM as add-on therapy in severe asthma,
and the differential effects can be used to position AZM in particular patient groups, such as those with
noneosinophilic severe asthma, and severe asthma with frequent infective bronchitis.
Severe asthma is defined in several ways. The key elements in each of the definitions are evidence of poor
control despite use of high intensity asthma therapy, which recognises the disease as being relatively
refractory to conventional asthma therapy. The main differences between the definitions relate to the
specified treatment intensity, in particular the ICS dose used. Patients receiving at least GINA step-4
treatment, which is a high-dose ICS and LABA, comprise the definitions based on GINA treatment levels
and the ISAR definition. Using these criteria, GINA step-4 ICS therapy equates to >1000 µg·d−1 of
beclomethasone dipropionate (CFC) or >500 µg·day−1 of fluticasone. The ATS/ERS severe asthma task
force definition is “asthma which requires treatment with guidelines suggested medications for GINA steps
4–5 (high-dose ICS and LABA or leukotriene modifier/theophylline)” [2]. There is some variation in the
specified ICS dose in the different definitions of severe asthma, both between different versions of the task





Serious adverse events 15/13 (13.5%) 22/14 (12.2%)
Cardiac 1/1 (1.0%) 2/2 (1.7%)
Gastrointestinal tract 4/3 (3.1%) 4/4 (3.5%)
Other health issue 5/4 (4.2%) 9/3 (2.6%)
Possible infectious serious adverse event 5/5 (5.2%) 5/3 (2.6%)
Events per person
No events 83 (86.5%) 101 (87.8%)
1 event 12 (12.5%) 10 (8.7%)
2 events 0 1 (0.9%)
3 events 1 (1.0%) 2 (1.7%)
4 events 0 1 (0.9%)
Study withdrawal (treatment discontinuation due to adverse
event)
7 (7.3%) 7 (6.1%)
Treatment-related adverse events
Nausea 6 (6.3%) 21 (18.3%)
Diarrhoea 22 (22.9%) 41 (35.7%)
Abdominal pain 16 (16.7%) 24 (20.9%)
Other gastrointestinal 2 (2.1%) 5 (4.4%)
Headache 2 (2.1%) 3 (2.6%)
Vertigo 0 1 (0.9%)
Tinnitus 1 (1.0%) 0
Hearing loss 4 (10.5%) 4 (6.8%)
High liver function tests results 2 (2.1%) 1 (0.9%)
Oral thrush 1 (1.0%) 4 (3.5%)
Allergy 0 1 (0.9%)
Rash 7 (7.3%) 4 (3.5%)
QTc prolongation 1 (2.6%) 3 (5.1%)
Other adverse event 17 (17.7%) 22 (19.1%)
Data are presented as n events/n (%) people, unless otherwise stated. QTc: corrected QT interval.
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force document, and with the GINA guidelines. The initial ATS/ERS task force document specified
high-dose ICSs as >1200 µg·day−1 of beclomethasone equivalent CFC. This was subsequently revised to
⩾2000 µg·day−1 of beclomethasone equivalent CFC MDI. In this paper, we evaluated the effect of AZM in
severe asthma, defined using each of the available definitions and found that AZM was effective in
reducing asthma exacerbations in each of the different ways that severe asthma was defined.
Macrolide antibiotics have both anti-infective and anti-inflammatory effects [7]. Corticosteroid
insensitivity is a feature of severe asthma, and in dynamic model systems, macrolides are effective in both
steroid sensitive (eosinophilic) and steroid insensitive (noneosinophilic) forms of the disease, which is
consistent with the results of the AMAZES trial [12]. There was not an obvious effect on sputum
granulocytes in the AMAZES trial, and other possibilities for the treatment effect of AZM include effects
on mucus production, macrophage function and antimicrobial effects. AZM also has promotility effects in
the gastrointestinal tract. It is hypothesised that these effects could reduce recurrent aspiration and this
may explain the beneficial effect of AZM on exacerbations.
The key effect of AZM was to reduce asthma exacerbations. The molecular mechanisms of these events are
an area of ongoing study. Airway gene expression for eosinophil and neutrophil genes is associated with
increased exacerbation frequency [13] but this effect does not appear to be modified by AZM. Other
potential mechanisms include activation of the interleukin-17 pathway, activation of epithelial
interleukin-6 pathways [14, 15] or improved bacterial clearance.
This study reports the results of an RCT of AZM in asthma. The main limitation is that the analysis is a
subgroup analysis of a previously reported study. Such analyses can be subject to bias; however, this seems
unlikely as the results are in agreement with the main study results, are consistent across different
definitions of severe asthma, and are consistent with other publications. A further limitation relates to a
reduction in sample size seen when performing analyses on subgroups, and this can preclude identification
of a statistically significant effect.
In conclusion, long-term low-dose oral AZM is effective in severe asthma. The treatment is well tolerated
and expected benefits are a significant reduction in severe exacerbations and improved quality of life. AZM
could be used before maintenance OCS and in severe noneosinophilic asthma. The order in which it is
best to add in macrolide therapy still requires elucidation, especially in relation to the sequence of
treatments added to ICSs and LABAs when patients are persistently symptomatic.
This study is registered at www.anzctr.org.au with identifier number ANZCTR12609000197235. Individual participant
data will not be made available. Other data and the study protocol will be available beginning 6 months and ending 2
years following data publication. These data may be shared with investigators whose proposed use of the data has been
approved by independent review committees (learned intermediary) identified for this purpose, with the data only being
used for analyses that achieve the aims in the approved protocol. Proposals for data access may be submitted up to 36
months following article publication. After 36 months, the data will be available in our university’s data system but
without investigator support other than deposited metadata.
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